Literature DB >> 20351267

Mig-6 controls EGFR trafficking and suppresses gliomagenesis.

Haoqiang Ying1, Hongwu Zheng, Kenneth Scott, Ruprecht Wiedemeyer, Haiyan Yan, Carol Lim, Joseph Huang, Sabin Dhakal, Elena Ivanova, Yonghong Xiao, Hailei Zhang, Jian Hu, Jayne M Stommel, Michelle A Lee, An-Jou Chen, Ji-Hye Paik, Oreste Segatto, Cameron Brennan, Lisa A Elferink, Y Alan Wang, Lynda Chin, Ronald A DePinho.   

Abstract

Glioblastoma multiforme (GBM) is the most common and lethal primary brain cancer that is driven by aberrant signaling of growth factor receptors, particularly the epidermal growth factor receptor (EGFR). EGFR signaling is tightly regulated by receptor endocytosis and lysosome-mediated degradation, although the molecular mechanisms governing such regulation, particularly in the context of cancer, remain poorly delineated. Here, high-resolution genomic profiles of GBM identified a highly recurrent focal 1p36 deletion encompassing the putative tumor suppressor gene, Mig-6. We show that Mig-6 quells the malignant potential of GBM cells and dampens EGFR signaling by driving EGFR into late endosomes and lysosome-mediated degradation upon ligand stimulation. Mechanistically, this effect is mediated by the binding of Mig-6 to a SNARE protein STX8, a protein known to be required for late endosome trafficking. Thus, Mig-6 functions to ensure recruitment of internalized receptor to late endosomes and subsequently the lysosomal degradation compartment through its ability to specifically link EGFR and STX8 during ligand-stimulated EGFR trafficking. In GBM, the highly frequent loss of Mig-6 would therefore serve to sustain aberrant EGFR-mediated oncogenic signaling. Together, these data uncover a unique tumor suppression mechanism involving the regulation of receptor trafficking.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351267      PMCID: PMC2872443          DOI: 10.1073/pnas.0914930107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Late endosomes derive from early endosomes by maturation.

Authors:  W Stoorvogel; G J Strous; H J Geuze; V Oorschot; A L Schwartz
Journal:  Cell       Date:  1991-05-03       Impact factor: 41.582

2.  DJ-1, a novel regulator of the tumor suppressor PTEN.

Authors:  Raymond H Kim; Malte Peters; YingJu Jang; Wei Shi; Melania Pintilie; Graham C Fletcher; Carmela DeLuca; Jennifer Liepa; Lily Zhou; Bryan Snow; Richard C Binari; Armen S Manoukian; Mark R Bray; Fei-Fei Liu; Ming-Sound Tsao; Tak W Mak
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

3.  DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras.

Authors:  D Nagakubo; T Taira; H Kitaura; M Ikeda; K Tamai; S M Iguchi-Ariga; H Ariga
Journal:  Biochem Biophys Res Commun       Date:  1997-02-13       Impact factor: 3.575

4.  DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses.

Authors:  Sophie Vasseur; Samia Afzal; Joël Tardivel-Lacombe; David S Park; Juan Lucio Iovanna; Tak Wah Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

5.  The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells.

Authors:  Takayuki Asano; Yixin Yao; Jijiang Zhu; Donghui Li; James L Abbruzzese; Shrikanth A G Reddy
Journal:  Oncogene       Date:  2004-11-11       Impact factor: 9.867

Review 6.  The quest for the 1p36 tumor suppressor.

Authors:  Anindya Bagchi; Alea A Mills
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 7.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

Authors:  Naoki Shinojima; Kenji Tada; Shoji Shiraishi; Takanori Kamiryo; Masato Kochi; Hideo Nakamura; Keishi Makino; Hideyuki Saya; Hirofumi Hirano; Jun-Ichi Kuratsu; Koji Oka; Yasuji Ishimaru; Yukitaka Ushio
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

10.  Down regulation of epidermal growth factor receptors: direct demonstration of receptor degradation in human fibroblasts.

Authors:  C M Stoscheck; G Carpenter
Journal:  J Cell Biol       Date:  1984-03       Impact factor: 10.539

View more
  58 in total

1.  Collateral Lethality: A new therapeutic strategy in oncology.

Authors:  Florian L Muller; Elisa A Aquilanti; Ronald A DePinho
Journal:  Trends Cancer       Date:  2015-11-01

2.  Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.

Authors:  Jeonghee Cho; Sandra Pastorino; Qing Zeng; Xiaoyin Xu; William Johnson; Scott Vandenberg; Roel Verhaak; Andrew D Cherniack; Hideo Watanabe; Amit Dutt; Jihyun Kwon; Ying S Chao; Robert C Onofrio; Derek Chiang; Yuki Yuza; Santosh Kesari; Matthew Meyerson
Journal:  Cancer Res       Date:  2011-10-14       Impact factor: 12.701

Review 3.  Endocytosis of receptor tyrosine kinases.

Authors:  Lai Kuan Goh; Alexander Sorkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

4.  Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.

Authors:  Zi-Xuan Li; Lian-Yue Qu; Hi Wen; Hong-Shan Zhong; Ke Xu; Xue-Shan Qiu; En-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.

Authors:  Hirofumi Ando; Tsutomu Miyamoto; Hiroyasu Kashima; Shotaro Higuchi; Koichi Ida; David Hamisi Mvunta; Tanri Shiozawa
Journal:  Horm Cancer       Date:  2017-05-17       Impact factor: 3.869

6.  Glucocorticoid-induced suppression of β-cell proliferation is mediated by Mig6.

Authors:  E Scott Colvin; Hong-Yun Ma; Yi-Chun Chen; Angelina M Hernandez; Patrick T Fueger
Journal:  Endocrinology       Date:  2013-02-05       Impact factor: 4.736

7.  Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.

Authors:  Christopher G Duncan; Patrick J Killela; Cathy A Payne; Benjamin Lampson; William C Chen; Jeff Liu; David Solomon; Todd Waldman; Aaron J Towers; Simon G Gregory; Kerrie L McDonald; Roger E McLendon; Darell D Bigner; Hai Yan
Journal:  Oncotarget       Date:  2010-08

Review 8.  Endocytosis and cancer.

Authors:  Ira Mellman; Yosef Yarden
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

9.  Disturbed cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of joint dysfunction.

Authors:  Michael A Pest; Bailey A Russell; Yu-Wen Zhang; Jae-Wook Jeong; Frank Beier
Journal:  Arthritis Rheumatol       Date:  2014-10       Impact factor: 10.995

10.  Mitogen-inducible gene 6 triggers apoptosis and exacerbates ER stress-induced β-cell death.

Authors:  Yi-Chun Chen; E Scott Colvin; Bernhard F Maier; Raghavendra G Mirmira; Patrick T Fueger
Journal:  Mol Endocrinol       Date:  2012-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.